Commercial
Advanced Search
  
  
  
  
  
  
  
  
  
  
  
MPattachmentdataPub
  
1601f15c-98e7-431c-8097-72bbc8db13e3.aspx
  
EvaluationandManagement(E&M)ofDiabeticPeripheralNeuropathywithLossofProtectiveSensation(LOPS)07.03.15d07.03.15dMedicine (07)Evaluation and Management (E&M) of Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS)1601f15c-98e7-431c-8097-72bbc8db13e38430Evaluation and Management (E&M) of Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS)07.03.155/29/2026 9:00 AM
6/24/2026
204d6e1f-bcbb-42d9-b74c-69a4b7058ad3.aspx
  
IntravitrealInjectionofVascularEndothelialGrowthFactor(VEGF)Antagonists,VEGFBiosimilars,andCombinationVEGF/Angiopoietin-2(Ang-2)Inhibitors08.00.74ad08.00.74adPharmacy (08)Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors204d6e1f-bcbb-42d9-b74c-69a4b7058ad38477Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors08.00.745/4/2026 3:00 PM
8/3/2026
55e7089b-0b2b-4910-8f00-7f924a4d6574.aspx
  
MultipleSurgeryPaymentReduction11.00.10z11.00.10zSurgery (11)Multiple Surgery Payment Reduction55e7089b-0b2b-4910-8f00-7f924a4d65748432Multiple Surgery Payment Reduction11.00.106/1/2026 10:00 AM
9/1/2026
1122d2ac-7f8e-4df4-aaf1-ba5d5f462d85.aspx
  
Tildrakizumab-asmn(Ilumya®)08.01.48c08.01.48cPharmacy (08)Tildrakizumab-asmn (Ilumya®)1122d2ac-7f8e-4df4-aaf1-ba5d5f462d858462Tildrakizumab-asmn (Ilumya®)08.01.486/12/2026 1:00 PM
9/14/2026